Stocktoria
CRISPR Therapeutics AG CRSP
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2016-10-19
CRISPR Therapeutics AG statistics & valuation
Market cap$5.3B
P / B2.8×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -18933.6% | -1250.4% | -60.0% | -56190.4% | 40.8% |
| Net margin | -16569.8% | -981.5% | -41.4% | -54271.7% | 41.3% |
| FCF margin | -9855.5% | -387.7% | -72.7% | -44484.9% | 50.0% |
| Return on assets | -25.7% | -16.3% | -6.9% | -29.0% | 13.7% |
| Return on equity | -30.3% | -19.0% | -8.2% | -34.7% | 15.7% |
| Debt / equity | 0.00× | — | — | — | — |
| Current ratio | 13.32 | 22.07 | 17.54 | 15.30 | 20.17 |
| Revenue growth | -90.6% | -89.9% | 30885.5% | -99.9% | 127154.9% |
Source: SEC EDGAR filings · CIK 0001674416 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.